Aquestive Therapeutics (AQST) Asset Writedowns and Impairment (2018 - 2019)
Aquestive Therapeutics (AQST) posted quarterly Asset Writedowns and Impairment of $6000.0 for Q3 2019, up 119.35% year-over-year from $2735.3 in Q3 2018, and down 75.0% quarter-over-quarter from $24000.0 in Q2 2019.
Aquestive Therapeutics (AQST) Asset Writedowns and Impairment (2018 - 2019) Analysis & Trends
Aquestive Therapeutics' Asset Writedowns and Impairment history runs 2 years deep, the most recent figure standing at $6000.0 for Q3 2019.
- In Q3 2019, Asset Writedowns and Impairment rose 119.35% year-over-year to $6000.0; the TTM figure through Sep 2019 stood at $89000.0 (changed N/A YoY), while the FY2018 annual figure was $53000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment for Q3 2019 stood at $6000.0, down from $24000.0 in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $53000.0 in Q4 2018, with the low at -$31000.0 in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Aquestive Therapeutics | 583.72 Mn | 583.72 Mn | 9.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 6,000.00 |
| Sep 30, 2019 | 6,000.00 |
| Jun 30, 2019 | 24,000.00 |
| Jun 30, 2019 | 24,000.00 |
| Mar 31, 2019 | 6,000.00 |
| Mar 31, 2019 | 6,000.00 |
| Dec 31, 2018 | 53,000.00 |
| Dec 31, 2018 | 53,000.00 |
| Sep 30, 2018 | -31,000.00 |
| Sep 30, 2018 | -31,000.00 |